Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Indaba Capital Management, L.P.

Q4 2024 · 13F-HR

Indaba Capital Management, L.P.holdings as filed

Filed 2025-02-14 · accession 0001011438-25-000175

$207.5M
Reported value
10
Positions
2024-12-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
69122G102BLUE OWL CAP CORP III$40.3M19.4%2,793,366CommonSOLE
05988JAD5BAND 0.5 04/01/28BANDWIDTH INC$32.2M15.5%40,250,000CommonSOLE
68339B104ONTFON24 INC$27.4M13.2%4,240,256CommonSOLE
761330AB5RVNC 1.75 02/15/27REVANCE THERAPEUTICS INC$24.0M11.6%25,000,000CommonSOLE
866082AA8INN 1.5 02/15/26SUMMIT HOTEL PPTYS$22.0M10.6%22,664,000CommonSOLE
294628102HP5AEQUITY COMWLTH$16.9M8.14%9,550,000CommonSOLE
46333XAH1IRWD 1.5 06/15/26IRONWOOD PHARMACEUTICALS INC$13.0M6.28%14,000,000CommonSOLE
761299AB2TVTX 2.5 09/15/25TRAVERE THERAPEUTICS INC$12.8M6.18%13,000,000CommonSOLE
00430HAC6ACCELERATE DIAGNOSTICS INC$12.3M5.95%24,685,998CommonSOLE
29664W105ESPRESPERION THERAPEUTICS INC NE$6.6M3.18%3,000,000CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.